Literature DB >> 22198955

Importance of antibody in virus infection and vaccine-mediated protection by a latency-deficient recombinant murine γ-herpesvirus-68.

Michael L Freeman1, Claire E Burkum, David L Woodland, Ren Sun, Ting-Ting Wu, Marcia A Blackman.   

Abstract

The human γ-herpesviruses EBV and Kaposi's sarcoma-associated herpesvirus establish lifelong latent infections, can reactivate in immunocompromised individuals, and are associated with the development of malignancies. Murine γ-herpesvirus-68 (γHV68), a rodent pathogen related to EBV and Kaposi's sarcoma-associated herpesvirus, provides an important model to dissect mechanisms of immune control and investigate vaccine strategies. Infection of mice with γHV68 elicits robust antiviral immunity, and long-term protection from γHV68 reactivation requires both cellular and humoral immune responses. Vaccination of mice with AC-replication and transcription activator (RTA), a highly lytic latency-null recombinant γHV68, results in complete protection from wild-type γHV68 infection that lasts for at least 10 mo. In this report, we examine the immune correlates of AC-RTA-mediated protection and show that sterilizing immunity requires both T cells and Ab. Importantly, Ab was also critical for mitigating viral infection in the brain, and in the absence of Ab-mediated control, amplification of the AC-RTA virus in the brain resulted in fatality. Our results highlight important considerations in the development of vaccination strategies based on live-attenuated viruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198955      PMCID: PMC3262927          DOI: 10.4049/jimmunol.1102621

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Latent antigen vaccination in a model gammaherpesvirus infection.

Authors:  E J Usherwood; K A Ward; M A Blackman; J P Stewart; D L Woodland
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.

Authors:  Tammy M Rickabaugh; Helen J Brown; DeeAnn Martinez-Guzman; Ting-Ting Wu; Leming Tong; Fuqu Yu; Steven Cole; Ren Sun
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Gammaherpesvirus persistence alters key CD8 T-cell memory characteristics and enhances antiviral protection.

Authors:  Joshua J Obar; Shinichiro Fuse; Erica K Leung; Sarah C Bellfy; Edward J Usherwood
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages.

Authors:  E Flaño; S M Husain; J T Sample; D L Woodland; M A Blackman
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  Murine gammaherpesvirus 68 encodes a functional regulator of complement activation.

Authors:  S B Kapadia; H Molina; V van Berkel; S H Speck; H W Virgin
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  A gamma-herpesvirus sneaks through a CD8(+) T cell response primed to a lytic-phase epitope.

Authors:  P G Stevenson; G T Belz; M R Castrucci; J D Altman; P C Doherty
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

7.  Murine gammaherpesvirus-68 infection of and persistence in the central nervous system.

Authors:  Linda A Terry; James P Stewart; Anthony A Nash; John K Fazakerley
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

8.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

9.  Age-dependent pathogenesis of murine gammaherpesvirus 68 infection of the central nervous system.

Authors:  Hye-Jeong Cho; Sungbum Kim; Sung-Eun Kwak; Tae-Cheon Kang; Hee-Sung Kim; Hyung-Joo Kwon; Yoon-Won Kim; Yong-Sun Kim; Eun-Kyung Choi; Moon Jung Song
Journal:  Mol Cells       Date:  2009-02-05       Impact factor: 5.034

10.  Gamma-herpesvirus latency is preferentially maintained in splenic germinal center and memory B cells.

Authors:  Emilio Flaño; In-Jeong Kim; David L Woodland; Marcia A Blackman
Journal:  J Exp Med       Date:  2002-11-18       Impact factor: 14.307

View more
  5 in total

1.  An attenuated duck plague virus (DPV) vaccine induces both systemic and mucosal immune responses to protect ducks against virulent DPV infection.

Authors:  Juan Huang; Renyong Jia; Mingshu Wang; Bing Shu; Xia Yu; Dekang Zhu; Shun Chen; Zhongqiong Yin; Xiaoyue Chen; Anchun Cheng
Journal:  Clin Vaccine Immunol       Date:  2014-01-22

2.  Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays.

Authors:  Isotta D'Arrigo; Emiliano Cló; Tomas Bergström; Sigvard Olofsson; Ola Blixt
Journal:  Glycoconj J       Date:  2013-01-08       Impact factor: 2.916

3.  Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice.

Authors:  Michael L Freeman; Claire E Burkum; Kathleen G Lanzer; Alan D Roberts; Mykola Pinkevych; Asako Itakura; Lawrence W Kummer; Frank M Szaba; Miles P Davenport; Owen J T McCarty; David L Woodland; Stephen T Smiley; Marcia A Blackman
Journal:  J Autoimmun       Date:  2012-12-14       Impact factor: 7.094

4.  Deletion of immune evasion genes provides an effective vaccine design for tumor-associated herpesviruses.

Authors:  Gurpreet Brar; Nisar A Farhat; Alisa Sukhina; Alex K Lam; Yong Hoon Kim; Tiffany Hsu; Leming Tong; Wai Wai Lin; Carl F Ware; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  NPJ Vaccines       Date:  2020-11-05       Impact factor: 7.344

5.  From Superantigens to "Real" Viral Antigens.

Authors:  Marcia A Blackman
Journal:  Viral Immunol       Date:  2020-04       Impact factor: 2.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.